Page 1

PRESS RELEASE Lyon , September 07 , 2021 L ADOCIA innovative medicine for everyone , everywhere Adocia Announces First Half 2021 Financial Results and Provides an Update on Activities • Cash position approximately € 20.7 million as of June 30 , 2021 ● Phase 3 submissions in China for Ultra - Rapid Insulin BioChaperone® Lispro • Launch of two clinical trials on combinations of insulin and amylin analogs : Phase 2 for M1Pram and proof - of - concept for BioChaperone® LisPram . Promising results and patent filings on cell therapy and obesity programs 6:00 pm CEST - Adocia ( Euronext Paris : FR0011184241 - ADOC ) , the clinical - stage biopharmaceutical company focused on the treatment of diabetes and other metabolic diseases with innovative formulations of proteins and peptides , announces today its financial results for the six months ended June 30th , 2021 . Half - year consolidated financial statements , expressed according to IFRS guidelines , underwent limited review by the statutory auditors and subsequently have been approved at the Board of Director's meeting held today . " Our strategy is based on the late - stage development of our ultra - rapid insulin in China and the studies launched on our insulin and amylin combinations , whose expected performance could significantly improve the treatment of diabetic patients . " Gérard Soula , CEO of Adocia , commented , " In parallel , the first results obtained in the fields of cell therapy and obesity are really promising . " 1/6